Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Cold Genesys is developing CG0070, a promising oncolytic virus that is proving successful in trials as a single agent, with near-term plans to develop it in combination with immuno-oncology agents.
Pacific Edge’s state-of-the-art suite of bladder cancer detection and management tests are noninvasive, highly effective, and more accurate than other urine-based cancer diagnostic tests, and are now being adopted into the standard of care.
Engineered agonist or antagonist versions of interleukin-2 (IL-2), IL-4, or IL-13 successfully stimulate tumor-killing immune cells or disrupt the tumor microenvironment while they synergize with other cancer immunotherapy platforms for potent, targeted treatment.
Melbourne-based Patrys has developed the Deoxymab platform, a unique technology able to produce antibodies that not only target and penetrate cancer cells, but bind to their DNA and block their repair enzymes, halting further progression.
The Center of Molecular Immunology, a core institute of the Cuban organization of Biotechnology and Pharmaceutical Industries, BioCubaFarma, specializes in the development and manufacture of monoclonal antibodies, immunomodulators and molecular vaccines for cancer immunotherapy.
BioWin, the health competitiveness cluster of Wallonia, Belgium, is the region’s point of reference across biopharma and medtech. Cancer immunotherapy has rapidly emerged as a focal point of BioWin’s uniquely collaborative ecosystem, owing to the local high density of cancer and immunology players.
Against the backdrop of a very deep and broad pipeline, the next breakthroughs in the immuno-oncology space will hinge on leveraging partnerships to improve existing therapies and to develop new strategies.
ABL Bio’s immuno-oncology programs are addressing the limitations of current checkpoint inhibitors by developing bispecific antibodies and the next generation of checkpoint inhibitors.
Karma Oncology combines a flexible virtual business model with expertise in oncology clinical trials to provide a bespoke contract clinical research service for biotechnology companies globally.
Swiss-based AMAL Therapeutics is developing KISIMA, a unique protein-based immunization platform capable of producing single therapeutic vaccines for immunotherapy and beyond.
Jaan Biotherapeutics is developing first-in-class therapies that repair damaged heart muscle and treat cardiovascular diseases by reactivating an endogenous regeneration process that has been shut down in the adult human heart during evolution, but is active in human fetal hearts.
Nutech Mediworld is addressing unmet medical needs including central nervous system disorders and dermatology indications with clinically validated allogenic stem cell therapy.
Promethera is developing HepaStem, a unique cell therapy that expresses mesenchymal stem cells with immunomodulatory properties suitable for the treatment of a number of hepatic diseases.
As a result of the recent landmark gene therapy and chimeric antigen receptor T cell approvals, momentum is building in the field of regenerative medicine. Increased funding and regulatory support has brought confidence to developers that are now bringing a new generation of concepts to the clinic.
Promedior, a clinical-stage biotechnology company, is developing immunotherapies to treat fibrosis. The company’s lead product candidate is PRM-151, a recombinant form of human pentraxin-2 formulated for intravenous injection.
Fibrosis is characterized by the excessive or abnormal accumulation of extracellular matrix within tissue, leading to organ dysfunction and disease in a range of conditions. There is a high level of unmet need given that the limited treatments available offer only modest benefits, and new drugs are urgently needed.
Taking a unique approach by targeting the virus host cell, Ansun BioPharma of San Diego, California is developing lead candidate Fludase (DAS181), which has shown potential for the treatment of parainfluenza, influenza and other viruses, including resistant strains.
A treatment for fatal lung diseases such as idiopathic pulmonary fibrosis is being developed by Lung Therapeutics. The novel mechanism could have wider applications for other fibrotic diseases.
